Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770777 | 0.86 | ADORA2A (0.33) | ALOX5APFEN1KDM4EHSD17B10MAPK14 | |
| SCHEMBL23770545 | 0.81 | DHFR (0.30) | — | |
| SCHEMBL23770577 | 0.80 | CDK9 (0.33) | ALOX5APFEN1 | |
| SCHEMBL23770438 | 0.79 | KDM4E (0.34) | KDM4EHSD17B10 | |
| SCHEMBL29464490 | 0.77 | PSMB1 (0.37) | ALOX5APFEN1KDM4EHSD17B10 | |
| SCHEMBL19925123 | 0.77 | PSMB1 (0.37) | ALOX5APFEN1KDM4EHSD17B10 | |
| SCHEMBL23770641 | 0.76 | ABL1 (0.41) | — | |
| SCHEMBL23770703 | 0.76 | ABL1 (0.35) | KDM4EHSD17B10 | |
| SCHEMBL23770696 | 0.74 | GAA (0.32) | KDM4EHSD17B10 | |
| SCHEMBL23770695 | 0.70 | CYP1A2 (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |